biotech / news / / FinanzNachrichten
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects.
The FDA has approved Eli Lilly's Foundayo (orforglipron) oral GLP-1 tablet for adult obesity.
KEY POINTS
- Foundayo can be taken at any time, unlike Wegovy, which requires fasting before intake.
- Foundayo showed higher rates of gastrointestinal side effects and discontinuation than semaglutide in trials.
- Lexaria's DehydraTECH technology reduced adverse events by 47.9% with oral semaglutide versus Rybelsus.
- Lexaria plans to test DehydraTECH with new GLP-1 drugs, including retatrutide, amycretin, and possibly orforglipron.
COMPANIES
Summarized by Newsio from FinanzNachrichten. How we summarize →